Holen Sie sich die Stockscreener-App
3.10
2.21%
-0.07
Handel nachbörslich:
3.07
-0.03
-0.97%
Schlusskurs vom Vortag:
$3.17
Offen:
$3.11
24-Stunden-Volumen:
7.37M
Relative Volume:
7.77
Marktkapitalisierung:
$428.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.44M
KGV:
-8.8571
EPS:
-0.35
Netto-Cashflow:
$-42.28M
1W Leistung:
+6.53%
1M Leistung:
+14.81%
6M Leistung:
-10.14%
1J Leistung:
+158.33%
1-Tages-Spanne:
$3.01
$3.305
1-Wochen-Bereich:
$2.66
$3.47
52-Wochen-Spanne:
$1.14
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie CMPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.10 | 438.36M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-02 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Eingeleitet | Guggenheim | Buy |
| 2025-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Eingeleitet | Jefferies | Buy |
| 2023-01-27 | Eingeleitet | Stifel | Buy |
| 2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
| 2021-12-22 | Eingeleitet | Raymond James | Outperform |
| 2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Compass Therapeutics Announces Public Offering to Raise $112.5M - TipRanks
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - Yahoo Finance
Real Time Data Flags Unusual Activity in Compass Therapeutics Inc.2025 Breakouts & Breakdowns & AI Enhanced Execution Alerts - 선데이타임즈
Compass Therapeutics sells $120M in stock; RemeGen to seek China approval - Endpoints News
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC - Seeking Alpha
Compass Therapeutics Posts Wider Q2 Loss - AOL.com
Compass, Inc. shares rise 2.48% premarket after Compass Therapeutics announced a $120 million public offering. - AInvest
Trend analysis for Compass Therapeutics Inc. this week2025 Key Lessons & Daily Technical Forecast Reports - Newser
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions - MSN
Compass Therapeutics Announces Proposed Public Offering - GlobeNewswire
Compass Therapeutics' $120M Equity Raise: A Strategic Move for Pipeline Advancement or a Dilution Risk? - AInvest
Compass Therapeutics prices $120 million public offering of common stock - Investing.com
Cancer Drug Developer Compass Therapeutics Secures $120M to Advance Commercial Plans - Stock Titan
Compass Therapeutics announces pricing of upsized $120 million public offering - MarketScreener
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - GlobeNewswire
Is Compass Therapeutics Inc. showing signs of accumulationControlled Entry Strategy With Safety Analytics - Newser
What recovery options are there for Compass Therapeutics Inc.Smart Entry Watchlist with Daily Analysis - Newser
Has Compass Therapeutics Inc. formed a bullish divergence [Treasury Yields]Free AI Driven Stock Price Forecasts - Newser
Compass Therapeutics Launches Public Offering of Common Shares - MarketScreener
Heatmap analysis for Compass Therapeutics Inc. and competitorsFree Stock Screener With Smart Filters - Newser
Compass Therapeutics announces public offering of common stock By Investing.com - Investing.com Nigeria
Compass Therapeutics Plans Stock Offering to Fund Cancer Drug Development - Stock Titan
Will Compass Therapeutics Inc. bounce back from current supportDaily Technical Chart Pattern Analysis Report - Newser
Compass Therapeutics: D. Boral Capital maintains Buy, PT raised to $32. - AInvest
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $7 to $24 - 富途牛牛
Compass Therapeutics: Guggenheim Raises PT to $12, Maintains Buy Rating - AInvest
Compass Therapeutics shares rise 1.20% premarket after reporting Q2 earnings and business update. - AInvest
Compass Therapeutics Inc (CMPX) Stock: A Year of Declines and Increases - investchronicle.com
Guggenheim raises Compass Therapeutics stock price target on promising clinical data - Investing.com Canada
Institutional Investors Have a Lot Riding on Compass Therapeutics, Inc. (NASDAQ:CMPX) With 46% Ownership - 富途牛牛
What makes Compass Therapeutics Inc. stock price move sharplyRisk/Reward Optimization Entry Point Analysis - Newser
Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ... By GuruFocus - Investing.com Canada
What does recent volatility data suggest for Compass Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
Compass Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating - AInvest
Using data filters to optimize entry into Compass Therapeutics Inc.Free Short Term High Yield Stock Tips - Newser
Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress - TipRanks
Using Ichimoku Cloud for Compass Therapeutics Inc. technicalsHigh Conviction Screener with Trend Matching - Newser
Compass Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Compass Therapeutics Soars 20.5% on Groundbreaking Clinical Data—What’s Next for the Biotech? - AInvest
Compass Therapeutics' shares rise 21% on positive pipeline updates. - AInvest
Compass Therapeutics stock rises on pipeline updates (CMPX) - Seeking Alpha
Compass Therapeutics Gains on Positive Cancer-Drug Survival Data - 富途牛牛
Compass Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
How to integrate Compass Therapeutics Inc. into portfolio analysis toolsFree Investment Plan With Growth Optimization - Newser
Transcript : Compass Therapeutics, Inc.Special Call - MarketScreener
Earnings call transcript: Compass Therapeutics Q2 2025 misses EPS expectations - Investing.com
Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Can volume confirm reversal in Compass Therapeutics Inc.Free Beginner Friendly Stock Selection Guide - Newser
What to expect from Compass Therapeutics Inc. in the next 30 daysReal-Time Equity Price Action Analysis - Newser
Compass Therapeutics Reports Promising Q2 2025 Results - TipRanks
Compass Therapeutics Grows R&D Spend And Extends Cash Runway - Finimize
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):